Skip to main content
. Author manuscript; available in PMC: 2019 Dec 3.
Published in final edited form as: Gut. 2016 Jan 4;66(4):724–735. doi: 10.1136/gutjnl-2015-310033

Figure 8. IFN-free therapy with DCV/ASV improves IFNα-signaling in NK cells.

Figure 8.

(A) Decrease in HCV RNA levels during the first 24h of IFN-free DCV/ASV therapy in 8 patients with an SVR.

(B, C) Fold-increase in the frequency (C) and mean fluorescence intensity (D) of pSTAT1+ NK cells in response to in vitro stimulation of PBMC with IFNα. The in vitro response to IFNα was assessed at day 0 and day 1 of DCV/ASV therapy. Statistical analysis: non-parametric paired Wilcoxon-signed-rank test.

(D, E) Fold-increase in the frequency (D) and mean fluorescence intensity (E) of pSTAT1+ NK cells in response to in vitro stimulation of PBMC with IFNα. The in vitro response to IFNα was assessed at day 0 and week 24 of DCV/ASV therapy. Statistical analysis: non-parametric paired Wilcoxon-signed-rank test.